Shots: On Completion of Acquisition Allergen will have global rights to EB-001A (aesthetic) and EB-001T (therapeutic) program currently under P-II trial Allergen will pay an upfront payment of $195M to Bonti addition to potential commercial milestone payments The focus of the acquisition is EB-001, a novel botulinum neurotoxin serotype E (BoNT/E), with rapid onset of […]Read More
